ArticleInfection and drug resistance2026
Multicenter Surveillance of
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the patient characteristics, resistance trends of Methods: WHONET 5.6 was employed to analyze patient characteristics of Kpn infections, resistance variations and CRKP prevalence using data from all 59 tertiary hospitals participating in Hebei Provincial Antimicrobial Resistance Surveillance System (HBARSS), 2019-2023. A total of 424 CRKP isolates from four hospitals across northern, central, and southern Hebei were subjected to antimicrobial susceptibility testing and whole-genome sequencing. Genomic analyses were performed using Kaptive, Kleborate, and PlasmidFinder. Results: Surveillance data showed that a total of 114,166 non-duplicate Kpn isolates were identified, including 16,681 CRKP. Kpn infections were more common in males (63.4%) and mainly occurred in elderly (54.1%) and ICU patients (20.2%). Resistance rates to most antimicrobials declined overall, except for minocycline, tigecycline and polymyxin B, which fluctuated. CRKP prevalence fell from 15.3% (2019) to 12.8% (2023), averaging 14.6%. Analysis of 424 clinical CRKP showed that Conclusion: Males, the elderly and ICU patients are susceptible populations. Despite declining resistance rate and CRKP prevalence in Hebei Province, China, hv-CRKP increased rapidly. And ST11-KL64 hv-CRKP and ST11-KL47 hv-CRKP showed different evolutionary patterns, with KL47 increasing more prominently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.